stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.18
0.82
+4.72%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) EPS (diluted)
Dyne Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$3.47, compared with −$3.37 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.33. Over the past ten years it has ranged from −$6.08 (fiscal 2019) to −$0.11 (fiscal 2018); the current reading is higher than 50% of that period. Dyne Therapeutics, Inc. ranks 391st of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.47 | — |
| FY2024 | −$3.37 | — |
| FY2023 | −$3.95 | — |
| FY2022 | −$3.23 | — |
| FY2021 | −$2.93 | — |
| FY2020 | −$4.13 | — |
| FY2019 | −$6.08 | — |
| FY2018 | −$0.11 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.08 | — |
| Mar 2026 | −$0.73 | — |
| Dec 2025 | −$0.76 | — |
| Sep 2025 | −$0.76 | — |
| 23 more quarters | Free account |
Against its own ten years
Low −$6.08
High −$0.11
Ten-year median
−$3.42
Current reading's percentile
50
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DNLI Denali Therapeutics Inc. compare | −$1.73 |
| DYN Dyne Therapeutics, Inc. | −$3.33 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| CELC Celcuity, Inc. compare | −$4.30 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item